483 related articles for article (PubMed ID: 26160192)
1. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
4. Mutation profile of high-grade appendiceal mucinous neoplasm.
Liao X; Vavinskaya V; Sun K; Hao Y; Li X; Valasek M; Xu R; Polydorides AD; Houldsworth J; Harpaz N
Histopathology; 2020 Feb; 76(3):461-469. PubMed ID: 31491041
[TBL] [Abstract][Full Text] [Related]
5. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival.
Singhi AD; Davison JM; Choudry HA; Pingpank JF; Ahrendt SA; Holtzman MP; Zureikat AH; Zeh HJ; Ramalingam L; Mantha G; Nikiforova M; Bartlett DL; Pai RK
Hum Pathol; 2014 Aug; 45(8):1737-43. PubMed ID: 24925222
[TBL] [Abstract][Full Text] [Related]
6. KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.
Matson DR; Xu J; Huffman L; Barroilhet L; Accola M; Rehrauer WM; Weisman P
Am J Case Rep; 2017 May; 18():558-562. PubMed ID: 28526814
[TBL] [Abstract][Full Text] [Related]
7. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.
Nishikawa G; Sekine S; Ogawa R; Matsubara A; Mori T; Taniguchi H; Kushima R; Hiraoka N; Tsuta K; Tsuda H; Kanai Y
Br J Cancer; 2013 Mar; 108(4):951-8. PubMed ID: 23403822
[TBL] [Abstract][Full Text] [Related]
8. Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.
Matsubara A; Sekine S; Ogawa R; Yoshida M; Kasamatsu T; Tsuda H; Kanai Y
Am J Surg Pathol; 2014 Mar; 38(3):370-6. PubMed ID: 24145653
[TBL] [Abstract][Full Text] [Related]
9. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review.
Stein A; Strong E; Clark Gamblin T; Clarke C; Tsai S; Thomas J; George B; Mogal H
Ann Surg Oncol; 2020 Jan; 27(1):85-97. PubMed ID: 31583543
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
12. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
13. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
14. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
[TBL] [Abstract][Full Text] [Related]
15. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
16. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
[TBL] [Abstract][Full Text] [Related]
17. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants.
LaFramboise WA; Pai RK; Petrosko P; Belsky MA; Dhir A; Howard PG; Becich MJ; Holtzman MP; Ahrendt SA; Pingpank JF; Zeh HJ; Dhir R; Bartlett DL; Choudry HA
Mod Pathol; 2019 Jul; 32(8):1197-1209. PubMed ID: 30962504
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.
Munari G; Businello G; Mattiolo P; Pennelli G; Sbaraglia M; Borga C; Pucciarelli S; Spolverato G; Mescoli C; Galuppini F; Sommariva A; Bellan E; Lonardi S; Loupakis F; Luchini C; Dei Tos AP; Fassan M
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1897-1904. PubMed ID: 33712927
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]